Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Making antisense of splicing.

Mariano A Garcia-Blanco1

  • 1Duke University Medical Center, Department of Molecular Genetics and Microbiology, Center for RNA Biology, Durham, NC 27710, USA. garci001@mc.duke.edu

Current Opinion in Molecular Therapeutics
|October 27, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Experimental validation of compound 3md, identified in silico, demonstrates antiviral effect on DENV2 by intervention in the replicative phase.

Virology·2026
Same author

Harnessing mRNA technology against <i>Fasciola hepatica</i>: Immunological insights from a fatty acid binding protein vaccine.

Frontiers in immunology·2025
Same author

Y-box binding proteins in immunity and RNA virus infection.

Microbiology and molecular biology reviews : MMBR·2025
Same author

Discovery of thiacyanine dyes as a new class of potent coronavirus inhibitors that suppress viral RNA synthesis.

The Journal of biological chemistry·2025
Same author

Host RNA-binding proteins and specialized viral RNA translation mechanisms: Potential antiviral targets.

Antiviral research·2025
Same author

Broad-spectrum antiviral ferruginol analog affects the viral proteins translation and actin remodeling during dengue virus infection.

Antiviral research·2025
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

Alternative splicing expands the proteome, offering therapeutic targets. Oligonucleotide-based therapies targeting splicing show promise for treating intractable conditions.

Area of Science:

  • Molecular biology
  • Genomics
  • Therapeutics

Background:

  • Alternative splicing significantly expands the proteome's coding capacity.
  • The splicing process itself presents a viable target for both conventional and molecular therapies.
  • A diverse pharmacoproteome arises from alternative splicing, offering numerous therapeutic targets.

Purpose of the Study:

  • To review splicing as a therapeutic target.
  • To emphasize oligonucleotide-based molecular approaches for splicing modulation.
  • To highlight the potential clinical utility of these novel therapeutic strategies.

Main Methods:

  • Focus on oligonucleotide-based molecular approaches.
  • Strategies include promoting constitutive exon skipping.

Related Experiment Videos

  • Methods also cover inhibiting aberrant exons and stimulating mutation-weakened exons.

    • Main Results:

    • Oligonucleotides can modulate alternative splicing outcomes.
    • Specific strategies demonstrated include exon skipping and modulation of exon activation/stimulation.
    • Preliminary results indicate significant potential for clinical application.

    Conclusions:

    • Alternative splicing modulation is a promising therapeutic strategy.
    • Oligonucleotide-based therapies offer a novel approach to targeting splicing.
    • These molecular approaches hold potential for treating previously intractable diseases.